Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.

NASDAQ:CYT

Cyteir Therapeutics, Inc.

Last Close

3.09

15/03 20:00

Market Cap

108.71M

Beta: -

Volume Today

1.01M

Avg: 56.88K

PE Ratio

−3.67

PFCF: −4.34